The Kremlin plans to resurrect Cold War-era concerns about the contested nuclear winter theory to reduce US support for Ukraine, Estonian intelligence…
The incident happened about a mile away from the venue of the Munich Security Conference, which is set to begin Friday.
The debate is not unique to India. In China, the infamous ‘996 culture’—where employees work from 9 am to 9 pm, six…
He claims the industry has exploited freshers for over a decade, with stagnant wages hitting the bottom 50% of employees.
Despite the company’s philanthropic image, employees often joked that the generosity could have been better spent on staff welfare and pay.
This decision comes as the demand environment picks up, with Infosys positioning itself to capitalise on the expected rise in IT spending
Nikhil Kamath asked Bryan Johnson if he could have it another way, with no money and no importance that comes with it,…
The conference is expected to attract over 1,000 delegates including global leaders and scholars, to discuss India’s expanding role on the world…
Health reporting at its worst is a recycled advisory or a pharmaceutical press release dressed up as news. This section tries to do something different — to cover health developments the way any serious beat deserves: with sourcing, context, and a clear sense of what changed and why it matters.
India's health story is more complicated than most headlines suggest. The same country that has produced a genuine first-of-its-kind antibiotic — Wockhardt's Zaynich, a fully indigenous compound developed against drug-resistant bacteria — is also an Ebola alert away from activating surveillance systems that have been dormant for years. Covering both with the same rigour is the job.
India manufactures roughly 20% of the world's generic medicines, but original drug research has historically been thin. That is slowly changing, and this section tracks it. Approvals matter not just as corporate news but as indicators of where India's pharmaceutical R&D is actually going — what disease areas are attracting investment, what regulatory pathways are being used, and what gaps in global medicine supply Indian companies are now positioned to fill.
When cases appear — Ebola in Bengaluru, Hantavirus on a cruise ship, an El Niño-linked disease surge — this section publishes what is confirmed by health authorities and not what is being speculated on social media. The WHO risk classifications, ICMR advisories, and state health department alerts are the primary sources. Outbreak coverage exists to inform, and the line between informing and alarming is one this section takes seriously.
Not every study deserves coverage. The ones that do are those that revise something previously assumed to be settled — like research confirming alcohol is linked to over 20 medical conditions, including several where "moderate drinking" was long considered safe. Or findings on toxin accumulation in high-puff vapes, a product category that arrived in the market faster than the science around it. These stories are covered when the evidence base is strong, not when the headline is convenient.
El Niño isn't just a weather event. It is a driver of vector-borne disease spread, food and water insecurity, and heat-related illness at a population scale. The UN's warnings on the current cycle belong in health coverage because that is where their consequences will eventually be felt — in hospital admission rates, in outbreak risk maps, in mortality data for vulnerable populations. This section covers climate-health links not as opinion but as epidemiology.
The Health section does not give medical advice. It reports health news — accurately, quickly, and without institutional cheerleading for any government body, pharmaceutical company, or health authority.
Pharmaceutical approvals, disease outbreaks, WHO and government health advisories, peer-reviewed research with clear public health implications, and the climate and environmental developments that drive disease risk. The coverage spans India-specific stories and global events where the consequences eventually reach Indian readers.
Yes, when WHO has formally classified the risk or when the outbreak trajectory makes spread plausible. The Congo Ebola outbreak was covered before the Bengaluru alert — because the international picture is how editors and readers alike should be tracking the timeline, not just reacting once a case arrives domestically.
Drug approvals are covered for what they mean clinically and for public health, not as company milestones. Zaynich's approval was reported in the context of antimicrobial resistance — a global health crisis — not as a Wockhardt earnings story. Where a drug matters, the coverage explains why. Where it doesn't, it isn't covered.
No. Research findings are covered when they carry genuine clinical or public health significance — not because they're trending. There are no diet tips, fitness advice, or wellness features here. Readers looking for that content are on the wrong page; readers looking for what the science actually says are in the right place.
Stories go up as confirmed information becomes available from official sources. During the Bengaluru Ebola alert, for instance, the priority was publishing what health authorities actually confirmed — not racing to be first with a worst-case interpretation. Speed matters, but not more than accuracy on a story where public anxiety can cause real harm.
Yes, consistently. Technical terms are defined on first use, clinical findings are explained in plain language, and regulatory or governmental processes are given context. The goal is a reader who knows nothing about antimicrobial resistance leaving a story on Zaynich understanding exactly why it matters — without the reporting being dumbed down for them.